DMXAA (vadimezan) is a STING (stimulator of interferon genes) agonist. DMXAA triggers the disruption of tumor vasculature, followed by hypoxia and cell death and the release of chemokines. These events lead to tumor regression. While STING agonist activity has accounted for antitumor activity in mice, DMXAA does not bind to human STING. In addition to its antitumor activities. DMXAA has also exhibited antiviral activity.